Twist Bioscience (NASDAQ:TWST) Trading 10.2% Higher – Should You Buy?

Twist Bioscience Co. (NASDAQ:TWST)’s stock price rose 10.2% during mid-day trading on Monday . The stock traded as high as $47.17 and last traded at $46.55. Approximately 399,057 shares traded hands during trading, a decline of 58% from the average daily volume of 948,770 shares. The stock had previously closed at $42.23.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of analyst reports. Robert W. Baird upped their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Evercore ISI increased their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Price Performance

The company has a fifty day moving average price of $43.78 and a 200 day moving average price of $46.15. The stock has a market cap of $2.75 billion, a P/E ratio of -12.89 and a beta of 1.78.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 3,310 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the sale, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at approximately $3,654,917.85. The trade was a 3.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,118 shares of company stock worth $4,391,151. Insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Several institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience during the third quarter worth about $34,000. Signaturefd LLC boosted its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $43,000. Blue Trust Inc. increased its position in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the second quarter worth $61,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.